December 13, 2005 Michael Becker President & Chief Executive Officer Cytogen Corporation 650 College Road East, Suite 3100 Princeton, NJ 08540 Dear Mr. Becker: The purpose of this letter agreement (the "Agreement") is to set forth the terms and...Introduction Agreement • December 14th, 2005 • Cytogen Corp • Pharmaceutical preparations
January 18, 2011 Chardan Capital Markets, LLC 17 State Street Suite 1600 New York, NY 10004 Re: Registered Direct Financing Ladies and Gentlemen:Introduction Agreement • January 20th, 2011 • Wizzard Software Corp /Co • Services-prepackaged software
This letter agreement (this “Agreement”) confirms our understanding and the terms and conditions under which Chardan Capital Markets, LLC (“Chardan”) shall introduce Wizzard Software Corporation, (the “Company”) to one or more investors (each an “Investor” and together the “Investors”). This Agreement relates exclusively to the proposed offering of up to 14 million shares of common stock securities of the Company (the “Securities”) pursuant to one or more subscription or purchase agreements to the extent entered into by the Company on or before the two week anniversary hereof (the “Offering”). The terms of such Offering and the Securities shall be mutually agreed upon by the Company and the Investors.
Rajesh Shrotriya, M.D. September 14, 2005 Chairman, CEO & President Spectrum Pharmaceuticals, Inc.Introduction Agreement • September 15th, 2005 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
The purpose of this letter agreement (the “Agreement”) is to set forth the terms and conditions pursuant to which Rodman & Renshaw, LLC (“R&R”) shall introduce Spectrum Pharmaceuticals, Inc. (the “Company”) to one or more investors in connection with the proposed public offering (the “Offering”) of securities (the “Securities”) of the Company which are registered on the Company’s Form S-3 Shelf Registration Statement, File No. 333-121612, which was declared effective by the Securities and Exchange Commission on January 24, 2005. The terms of such Offering and the Securities shall be mutually agreed upon by the Company and the investor(s). R&R’s engagement under this Agreement shall be non-exclusive. Unless the Company has prior knowledge of the existence of such investors, the identities of the investors to which R&R introduces the Company shall be proprietary information of R&R and shall not be divulged to third parties by the Company, nor shall such information be used by the Company
Glenn Argenbright President & Chief Executive Officer SAFLINK CorporationIntroduction Agreement • June 13th, 2005 • Saflink Corp • Services-computer programming, data processing, etc. • New York
EXHIBIT 10.1 July 20, 1999 Mr. David B. Stocker, Esq. 4745 North 7th Street, Suite 234 Phoenix, Arizona 85014 Re: Autocapital - Wapro B.V. Dear Mr. Stocker: Your office represents Autocapital with regard to the merger with Wapro B.V. This letter sets...Introduction Agreement • August 1st, 2000 • Royal Waterlily Inc • Arizona
April 11, 2002Introduction Agreement • April 12th, 2002 • Ellin Robert S • Plastics products, nec
Conditions for the Introduction of CandidatesIntroduction Agreement • August 5th, 2022
ContractIntroduction Agreement • May 30th, 2013
Switchboard: 01752 229 214 Facsimile: 01752 451 953 Freephone: 0800 012 4180 Directors: Chairman: Paul Starkey Managing Director: Steven Wilkie E:info@responsibleequityrelease.co.uk W:www.responsibleequityrelease.co.uk Unit 11, 4a Mills Bakery, Royal William Yard Plymouth PL1 3GE
Exhibit 10.1 Univest Capital Limited __________________________________________ ______________________________________ Meierhofstrasse 2 FL-9490 Vaduz December 3, 2005 Mr. Walter Witoshkin QuantRx Biomedical Corporation 321 Norristown Road, Suite 230...Introduction Agreement • March 31st, 2006 • Quantrx Biomedical Corp • Surgical & medical instruments & apparatus • Pennsylvania
This agreement shall be governed by the laws of the State of Pennsylvania, without regard to conflicts of law principle. Any dispute arising out of this agreement shall be adjudicated in the courts of the State of Pennsylvania or in the federal courts sitting in the Eastern District.
William Keane Chief Financial Officer Genta lncorporated Two Connell Drive Berkeley Heights, NJ 07922 December 6,2004Introduction Agreement • December 16th, 2004 • Genta Inc De/ • Biological products, (no disgnostic substances)
The purpose of this letter agreement (the "Agreement") is to set forth the terms and conditions pursuant to which Rodman & Renshaw, LLC ("R&R) shall introduce Genta lncorporated (the "Company") to one or more investors in connection with the proposed offering (the "Offering") of securities (the "Securities") of the Company. The terms of such Offering and the Securities shall be mutually agreed upon by the Company and the investor(s). R&R's engagement under this Agreement shall be exclusive until December 15, 2004, and thereafter shall be non-exclusive. The identities of the investors to which R&R introduces the Company shall be proprietary information of R&R and shall not be divulged to third parties by the Company, nor used by the Company outside the scope of R&R's engagement as described herein.
Mr. George S. Young President & CEO Fellows Energy Broomfield, CO 80021 Dear Mr. Young:Introduction Agreement • March 31st, 2005 • Fellows Energy LTD • Oil & gas field exploration services
As set forth herein, this letter confirms our agreement with respect to Axiom Capital Management, Inc.’s (“Axiom”) introduction of John McGrain, Jed Oil, Enterra Energy, and JMG Exploration (together with their affiliates and controlled persons, the “Introduced Persons”) to Fellows Energy (the “Company”) in connection with the following contemplated transactions, as well as any other transactions that may be engaged in by and between any Introduced Persons and the Company (collectively, the “Transactions”):
ContractIntroduction Agreement • December 4th, 2020 • England
PLEASE READ THESE TERMS OF AGREEMENT CAREFULLY AS THEY ARE BINDING UPON YOU.Introduction Agreement • April 13th, 2015
These terms govern the introduction of a contractor by Churchill Frank International, a trading name of Nigel Frank International Ltd (“Churchill Frank”) to you (“the Client”) prior to formal terms of business being agreed.
March 20, 2006Introduction Agreement • March 21st, 2006 • Novavax Inc • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (the “Agreement”) is to set forth the terms and conditions pursuant to which Rodman & Renshaw, LLC (“R&R”) shall introduce Novavax, Inc. (the “Company”) to one or more investors in connection with the proposed offering (the “Offering”) of securities (the “Securities”) of the Company. The terms of such Offering and the Securities shall be mutually agreed upon by the Company and the investor(s). R&R’s engagement under this Agreement shall be exclusive until March 23, 2006, and thereafter shall be non-exclusive. The identities of the investors to which R&R introduces the Company shall be proprietary information of R&R and shall not be divulged to third parties by the Company, nor used by the Company outside the scope of R&R’s engagement as described herein, other than as required by applicable law.
PLEASE READ THESE TERMS OF AGREEMENT CAREFULLY AS THEY ARE BINDING UPON YOU.Introduction Agreement • April 13th, 2015
These terms govern the introduction of a contractor by Nigel Frank International Ltd (“Nigel Frank”) to you (“the Client”) prior to formal terms of business being agreed.
Rahul Singhvi President / Chief Executive Officer Novavax, Inc. 508 Lapp Road Malvern, PA 19355 Dear Mr. Singhvi:Introduction Agreement • November 2nd, 2005 • Novavax Inc • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (the “Agreement”) is to set forth the terms and conditions pursuant to which Rodman & Renshaw, LLC (“R&R”) shall introduce Novavax, Inc. (the “Company”) to one or more investors in connection with the proposed offering (the “Offering”) of securities (the “Securities”) of the Company. The terms of such Offering and the Securities shall be mutually agreed upon by the Company and the investor(s). R&R’s engagement under this Agreement shall be exclusive until November 4, 2005, and thereafter shall be non-exclusive. The identities of the investors to which R&R introduces the Company shall be proprietary information of R&R and shall not be divulged to third parties by the Company, nor used by the Company outside the scope of R&R’s engagement as described herein, other than as required by applicable law.
Edward Taylor Vice President of Finance, Chief Financial Officer Biomira Inc. 2011-94th Street Edmonton, AB T6N 1H1, Canada Dear Mr. Taylor:Introduction Agreement • September 12th, 2007 • Biomira CORP • New York
The purpose of this letter agreement (the "Agreement") is to set forth the terms and conditions pursuant to which Rodman & Renshaw, LLC ("R&R") shall introduce Biomira Inc. (the "Company") to one or more investors in connection with the currently proposed offering (the "Offering") of securities (the "Securities") of the Company. The terms of such Offering and the Securities shall be mutually agreed upon by the Company and the investor(s). The identities of the investors to which R&R introduces the Company (the "Investors") shall be proprietary information of R&R and shall not be divulged to third parties by the Company, nor used by the Company outside the scope of R&R's engagement as described herein.
Rodeman & Renshaw, LLC Letterhead]Introduction Agreement • June 2nd, 2005 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
August 10, 2001Introduction Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
Titan Pharmaceuticals, Inc.Introduction Agreement • March 16th, 2006 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
ATLANTIS EQUITIES, INC. 750 LEXINGTON AVENUE, 23rd FLOOR NEW YORK, NEW YORK 10022 TEL: (212) 755-8612 FAX: (212) 750-6667 April 11, 2002Introduction Agreement • April 16th, 2002 • Forward Industries Inc • Plastics products, nec
As discussed, the purpose of this letter is to confirm our understanding with respect to the introduction by Atlantis Equities, Inc., a New York corporation ("Atlantis"), to Forward Industries, Inc., a New York corporation (the "Company"), of a company called for purposes of this letter XYZ Corp. ("XYZ") for the purpose of the Company's consideration of a proposed financial transaction, which may be in the form of an acquisition or business combination involving XYZ (the "Transaction"). XYZ has authorized Atlantis to make such introduction for the purposes stated herein.
Sonder terms and conditions for the introduction of candidates – Strictly Private & ConfidentialIntroduction Agreement • October 2nd, 2024
Adya Tripathi President & Chief Executive Officer Tripath Technology, Inc.Introduction Agreement • March 4th, 2005 • Tripath Technology Inc • Semiconductors & related devices • New York
EXHIBIT 10.3 [GRAPHIC OMITTED] November 1, 2005 Walter W. Witoshkin QuantRx Biomedical Corporation (Formerly A-Fem Medical Corporation) 321 Norristown Road Suite 230 Ambler, PA 19002 Dear Mr. Witoshkin: The purpose of this letter agreement (the...Introduction Agreement • March 31st, 2006 • Quantrx Biomedical Corp • Surgical & medical instruments & apparatus • Florida
Walter W. Witoshkin QuantRx Biomedical Corporation (Formerly A-Fem Medical Corporation) 321 Norristown Road Suite 230 Ambler, PA 19002
ContractIntroduction Agreement • March 26th, 2004 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Louis R. Bucalo, M.D. President & Chief Executive Officer Titan Pharmaceuticals, Inc. 400 Oyster Point Blvd., Suite 505 South San Francisco, CA 94080
February 5, 2002Introduction Agreement • July 10th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations
PLEASE READ THESE TERMS OF AGREEMENT CAREFULLY AS THEY ARE BINDING UPON YOU.Introduction Agreement • June 21st, 2017
These terms govern the introduction of a contractor by FRG Technology Consulting, a trading name of Nigel Frank International Ltd (“FRG Technology Consulting”) to you (“the Client”) prior to formal terms of business being agreed.
EXHIBIT 1(a) Jack Schwebel Schwebel Capital Investments, Inc. 10451 Mill Run Circle Owings Mills, MD 21117 Dear Jack: This letter, together with Schedules A, B, C & D, constitutes our agreement (the "Agreement") between Noise Cancellation...Introduction Agreement • January 27th, 1997 • Noise Cancellation Technologies Inc • Miscellaneous electrical machinery, equipment & supplies • Delaware
Jesup & Lamont SECURITIES CORPORATIONIntroduction Agreement • February 16th, 2005 • Qiao Xing Universal Telephone Inc • Telephone & telegraph apparatus • New York
Mr. Rui LinWu Chairman & Chief Executive Officer Qiao Xing Universal Telephone, Inc Qiao Xing Building, Huizhou City Guangdong, 51602
Denis Burger, Ph.D. Chairman and CEO AVI BioPharma, Inc. One S.W. Columbia Street, Suite 1105 Portland, OR 97258 Dear Dr. Burger:Introduction Agreement • November 21st, 2005 • Avi Biopharma Inc • Pharmaceutical preparations • New York
The purpose of this letter agreement (the “Agreement”) is to set forth the terms and conditions pursuant to which Rodman & Renshaw, LLC. (“R&R”) shall introduce AVI BioPharma, Inc. (the “Company”) to one or more investors in connection with the proposed offering (the “Offering”) of securities (the “Securities”) of the Company. The gross proceeds from the Offering will be up to $27,000,000. The terms of such Offering and the Securities shall be mutually agreed upon by the Company and the investor(s). R&R’s engagement under this Agreement shall be exclusive until the earlier of (i) the completion of the Offering or (ii) December 31, 2005. The identities of the investors to which R&R introduces the Company shall be proprietary information of R&R and shall not be divulged to third parties by the Company, nor used by the Company outside the scope of R&R’s engagement as described herein.
